Citadel Advisors
IRON icon

Citadel Advisors’s Disc Medicine IRON Stock Holding History

Citadel Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
+20,900
New +$1.45M ﹤0.01% 6988
2025
Q4 		– Sell
-3,900
Closed -$258K – 13354
2025
Q3 		$258K Sell
3,900
-16,600
-81% -$987K ﹤0.01% 10694
2025
Q2 		$1.09M Buy
20,500
+20,000
+4,000% +$939K ﹤0.01% 6917
2025
Q1 		$24.8K Buy
500
+100
+25% +$5.56K ﹤0.01% 12984
2024
Q4 		$25.4K Sell
400
-2,600
-87% -$150K ﹤0.01% 13018
2024
Q3 		$147K Sell
3,000
-8,400
-74% -$394K ﹤0.01% 10584
2024
Q2 		$514K Sell
11,400
-2,800
-20% -$95.1K ﹤0.01% 7986
2024
Q1 		$884K Buy
14,200
+12,200
+610% +$791K ﹤0.01% 7169
2023
Q4 		$116K Buy
+2,000
New +$102K ﹤0.01% 10751
2022
Q4 		– Sell
-723
Closed -$36K – 15158
2022
Q3 		$36K Buy
723
+170
+31% +$8.02K ﹤0.01% 11807
2022
Q2 		$28K Buy
+553
New +$24.5K ﹤0.01% 12261
2021
Q4 		– Sell
-363
Closed -$44K – 14277
2021
Q3 		$44K Sell
363
-554
-60% -$75.7K ﹤0.01% 13428
2021
Q2 		$178K Buy
+917
New +$302K ﹤0.01% 12300

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors's IRON Position: Q1 2026 in Review

Citadel Advisors reduced its Disc Medicine (IRON) stake by 2.5% in Q1 2026, selling an estimated $171K and leaving 97,930 shares worth $6.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3982.

Citadel Advisors first reported a position in IRON in Q1 2021 and has held it in 20 quarters since. The position peaked at $37.5M in Q4 2024. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Citadel Advisors held 97,930 shares of Disc Medicine worth $6.26M as of Q1 2026.
  • Citadel Advisors sold 2,465 Disc Medicine shares in Q1 2026, an estimated $171K.
  • Disc Medicine made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3982 holding.
  • Citadel Advisors first reported a position in Disc Medicine in Q1 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Disc Medicine position peaked at $37.5M in Q4 2024.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.